Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

The European Union and personalised cancer medicine.

European journal of cancer (Oxford, England : 1990) - 1 Jun 2021

Hickman John A, Tannock Ian F, Meheus Lydie, Hutchinson Lisa

Abstract excerpt

Two recent policy documents by the European Union, 'Europe's Beating Cancer Plan' and its accompanying 'Conquering Cancer: Mission Possible' (CCMP), articulate broad policies aimed at reducing cancer mortality across Europe, for example, by promoting prevention and early detection. The focus for cancer treatment in these manifestos is the expansion of personalised cancer medicine (PCM). However, the CCMP document...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Risk Assessment
Share to Antineoplastic Agents
Share to Biomarkers, Tumor

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Drug Resistance, Neoplasm

Share to Europe

Share to Genetic Heterogeneity

Share to Molecular Targeted Therapy

Share to Precision Medicine

Source

Identifiers

PMID: 33892410
DOI: 10.1016/j.ejca.2021.03.013

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 6 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

The European Union and personalised cancer medicine.PMID 33892410Read ↗

Basic cancer research is essential for the success of personalised medicine.Semantic proximity Read ↗

Moving pan-cancer studies from basic research toward the clinic.Semantic proximity Read ↗

Bringing onco-innovation to Europe’s healthcare systems: the unexploited potential of biomarker testing, real world evidence and the potential of Tumour Agnostics. The lesson from BRCA1/2 genetic testingSemantic proximity Read ↗

Lesionalized therapy beyond personalized therapy in cancer management.Semantic proximity Read ↗

Improving public cancer care by implementing precision medicine in Norway - IMPRESS-NorwaySemantic proximity Read ↗

Untangling the roots of cancer.Semantic proximity Read ↗

Personalised cancer medicine.Semantic proximity Read ↗

Achieving personalized cancer medicine: trials and tribulations.Semantic proximity Read ↗

Embracing cancer complexity: Hallmarks of systemic diseaseSemantic proximity Read ↗

Precision medicine based on epigenomics: the paradigm of carcinoma of unknown primarySemantic proximity Read ↗

Nothing in cancer makes sense except….Semantic proximity Read ↗

Next-generation sequencing and empowering personalised cancer medicineSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.